This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joly, V. Search for Related Content PubMed PubMed Citation Articles by Joly, V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2000, p. 3155-3157, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial

Véronique Joly,^1,* Mauro Moroni,² Ercole Concia,³ Adriano Lazzarin,⁴ Bernard Hirschel,⁵ Josef Jost,⁶ Francesco Chiodo,⁷ Zvi Bentwich,⁸ W. Campbell Love,⁹ David A. Hawkins,¹⁰ Edmund G. L. Wilkins,¹¹ Aritigas J. Gatell,¹² Norbert Vetter,¹³ Cynthia Greenwald,¹⁴ William W. Freimuth,¹⁴ Wanda de Cian,¹⁴ and The M/3331/0013B Study Group

Department of Internal Medicine, Hôpital Bichat, Paris, France¹; Division of Infectious Disease, Ospedale Luigi Sacco,² Division of Infectious Disease, Ospedale S. Raffaele,⁴ and The Pharmacia & Upjohn Company,¹⁴ Milan, Division of Infectious Disease Ospedale S. Orsola, Bologna,⁷ and Division of Infectious Disease, Ospedale Borgo Roma, Verona,³ Italy; and Division of Infectious Disease, Hôpital Cantonal Universitaire, Geneva,⁵ and Division of Infectious Disease, Universitatsspital Abteilung, Zurich,⁶ Switzerland; Clinical Immunology, Kaplan Hospital, Rehovet, Israel⁸; Department of Infection and Tropical Medicine, Ruchill Hospital, Glasgow,⁹ Kolber Center, London,¹⁰ and Department of Infectious Disease, North Manchester General Hospital, Manchester,¹¹ United Kingdom; Division of Infectious Disease, Hospital Clinico y Provencialo, Barcelona, Spain¹²; and Medical Department, Wiener Wald Pulmologisches Zentrum Sanatorium, Vienna, Austria¹³

Received 13 December 1999/Returned for modification 7 February 2000/Accepted 1 August 2000

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

---

^* Corresponding author. Mailing address: Médecine Interne, Hôpital Bichat, 46 rue Henri Huchard, 75877 Paris Cedex 18, France. Phone: 33 1 40 25 70 02. Fax: 33 1 40 25 88 45. E-mail: veronique.joly{at}bch.ap-hop-paris.fr.

Members are listed in the appendix.

---

Antimicrobial Agents and Chemotherapy, November 2000, p. 3155-3157, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Joly, V., Descamps, D., Peytavin, G., Touati, F., Mentre, F., Duval, X., Delarue, S., Yeni, P., Brun-Vezinet, F. (2004). Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs. Antimicrob. Agents Chemother. 48: 172-175 [Abstract] [Full Text]  
• Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]